An Overview of the Mechanisms Involved in Neuralgia

Bai-Wen Zhang¹, Hao Dong¹, Zhe Wu¹, Xi Jiang², Wei Zou³

¹Heilongjiang University of Chinese Medicine, Harbin, 150040, People’s Republic of China; ²Jinzhou Medical University, Jinzhou, 121001, People’s Republic of China; ³The Third Department of Acupuncture and Moxibustion, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, 150040, People’s Republic of China

Correspondence: Wei Zou, The Third Department of Acupuncture and Moxibustion, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, 150040, People’s Republic of China, Tel +86 0451-82161746, Email weizouzw@126.com

Abstract: Neuralgia is a frequently occurring condition that causes chronic pain and burdens both patients and their families. Earlier research indicated that anti-inflammatory treatment, which was primarily utilized to address conditions like neuralgia, resulted in positive outcomes. However, recent years have witnessed the emergence of various novel mechanisms associated with pain-related disorders. This review provides a concise overview of the inflammatory mechanisms involved in neuralgia. It also examines recent advancements in research, exploring the influence of ion channels and synaptic proteins on neuralgia and its complications. Additionally, the interactions between these mechanisms are discussed with the aim of suggesting innovative therapeutic approaches and research directions for the management of neuralgia.

Keywords: neuralgia, inflammatory mechanisms, innovative therapeutic approaches

Introduction

The International Association for the Study of Pain (IASP) provides a definition for pain as a distressing sensory and emotional experience that is associated with actual or potential damage to tissues, or similar sensations.¹ The involvement of the nervous system in transmitting sensations between peripheral receptors and the central nervous system is a crucial aspect of this process.²,³ Statistics indicate that over 30% of the global population experiences chronic pain annually, with approximately 15–25% of chronic pain being neuropathic.⁴

Trauma, surgery, ischemia, inflammation, viruses, chemotherapy, autoimmune diseases, and channelopathies are all factors that can cause nerve damage, specifically affecting the somatosensory system. The occurrence of thermal hyperalgesia and tactile allodynia (increased sensitivity to heat and pain from touch) in the body can be used to determine the presence of these diseases. In the ICD-11 classification, neuropathic pain is categorized as either central neuropathic pain or peripheral neuropathic pain, depending on the location of the lesion. Central neuropathic pain is caused by damage or disease in the central somatosensory nervous system, which may result from central sensitization (lowered pain threshold or increased response to nociceptive input), including punctate hyperalgesia, ongoing pain, dysesthesia, afferentations, and temporal summation. Examples of conditions causing central neuropathic pain include stroke, traumatic brain injury, and multiple sclerosis. Spinal cord injury is the most common cause, with approximately 50% of patients experiencing central pain. Peripheral sensitization primarily caused by mechanical insensitivity of C fibers and resulting in pain hypersensitivity and abnormal pain perception is the main cause of peripheral neuropathic pain. This can be seen in conditions such as trigeminal neuralgia, postherpetic neuralgia, and carpal tunnel syndrome (Figure 1).⁵,⁶

Neuralgia can also lead to complications such as depression, anxiety, and disrupted sleep, which further exacerbate and perpetuate the pain.⁴ Recent research suggests that while anti-inflammatory mechanisms are important for treatment, exploring the impact of ion channels and synaptic proteins on the condition may offer new therapeutic possibilities.
Effect of Cytokines on the Sensitization of Pain Sense

After nerve injury, various cell factors are upregulated in DRG neurons, increasing neuronal excitability and driving peripheral sensitization. Excitatory synaptic transmission mediated by N-methyl-D-aspartate receptors (NMDAR) and α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors (AMPAR) reduces inhibitory synaptic transmission mediated by GABA receptors and glycine receptors, leading to central sensitization. 7–10

Calcitonin gene-related peptide (CGRP) is a pain-inducing factor that contributes to the development of hyperalgesic responses in nerve injury. It is released from the central terminals of nociceptors, promoting central sensitization, 11 and its expression is upregulated in response to inflammatory signaling. 12,13 This further exacerbates pain occurrence. Pathological activity of peripheral incoming nerves after injury leads to the release of colony-stimulating factor 1 (CSF1) from damaged afferent neurons, triggering activation of microglia through the activation of CSF receptor 1 on their surface or via the AMPK signaling pathway. 14

In the spinal cord, parenchymal microglia are the sole cells expressing colony-stimulating factor 1 receptor (CSF1R). The cross-talk between CSF1-mediated spinal microglia and lymphocytes can either amplify or inhibit pain. 15 Substance P (SP) is an 11-amino acid neuropeptide that preferentially activates the neurokinin-1 receptor (NK1R). SP is expressed in several central nervous system regions, including the substantia nigra, amygdala, dorsal root ganglia (DRG), and dorsal horn, and plays a role in transmitting nociceptive signals from primary afferent fibers to secondary neurons in the spinal cord and brainstem. 16 SP is also expressed in microglia, T cells, macrophages, and eosinophils. During inflammation, upregulated SP released by primary afferent fibers binds to NK1 receptors on dorsal horn neurons, activating phospholipase C signaling cascade and subsequently modulating membrane depolarization and the function of AMPAR and NMDAR. This regulation affects spinal neuron excitability and plays a crucial role in pain hypersensitivity. Additionally, SP can regulate pathways like nuclear factor kappa-B (NF-κB) and PPAR to alleviate pain. 17,18 NMDARs, particularly subtypes NR2A and NR2B, are key regulatory subunits controlling NMDAR channels 19 that play a critical role in neuropathic and inflammatory pain. Increased NMDAR expression leads to glial cell activation as well as reduced Kir4.1 expression, resulting in augmented intracellular calcium influx and activation of protein kinases. This initiates cellular cascades that modulate membrane properties and neuronal sensitivity, thereby contributing to central sensitization. 20–22

Furthermore, inflammatory mediators such as bradykinin, prostaglandins, nerve growth factor, and pro-inflammatory cytokines like tumor necrosis factor-alpha, interleukin-1beta, and pro-inflammatory chemokines can directly bind to and activate or sensitize G protein-coupled receptors, ion channels, and tyrosine kinase receptors located on the terminals and/or cell bodies of nociceptors. This activation or sensitization ultimately leads to the generation of pain in the body. 23–25
A study revealed that the expression of chemokines and their receptors, specifically CX3CL1/CX3CR1, CCL2/CCR2, CXCL1/CXCR2, CXCL12/CXCR4, and CCL3/CCR5, was increased during the onset of neuropathic pain.26

Fractalkine, also known as C-X3-C Motif Chemokine Ligand 1 (CX3CL1), is expressed in primary sensory neurons and spinal neurons and induces activation of microglia through its receptor CX3CR1 (neuron-to-microglia signaling).27 CCL2 and CXCL1 are expressed in spinal astrocytes and act on CCR2 and CXCR2 in spinal neurons, increasing excitatory synaptic transmission.28 CCL2, also called Monocyte chemoattractant protein-1 (MCP-1), is a pain-related chemokine present in substance P (SP) and calcitonin gene-related peptide (CGRP)-positive primary sensory neurons in the superficial dorsal horn. It directly contributes to central sensitization by binding to CCR2. In a rat model of Central post-stroke pain (CPSp), MCP-1 expression levels are elevated in bilateral dorsal horns of the spinal cord, leading to glial activation through neuronal-glia interactions mediated by CCR2.29 Additionally, electrophysiological studies have demonstrated that MCP-1 enhances NMDA and AMPA-induced currents, increasing the frequency of sEPSCs (spontaneous excitatory postsynaptic currents) in spinal second-order neurons and exacerbating inflammatory pain severity.30 Conversely, inhibiting MCP-1 signaling can alleviate various types of pain by reducing neuronal excitability, microglial activation, and release of pro-inflammatory cytokines observed in multiple pain models.31,32

CXCL1 is expressed and secreted by activated macrophages, endothelial cells, and fibroblasts. It is expressed in spinal astrocytes and neurons, inducing CXCR2-dependent thermal hyperalgesia. CXCL1 is also involved in various downstream pathways such as c-Raf/MAPK/AP-1, p-PKC-μ/p-ILK/NLRP3, JAK2/STAT3, TAK1/NF-κB.33 Electrophysiological recordings demonstrate that CXCL1 increases NMD-induced currents in dorsal horn neurons through CXCR2.34,35 In a rat model of neuropathic pain following injury, CXCL12 expression is upregulated in the spinal cord and dorsal root ganglia.36 CXCL12 is expressed in neurons, astrocytes, and microglia. Its binding to CXCR4 leads to excessive excitation of glutamatergic neurons, contributing to pain sensitization.37,38 The interaction between CXCL12 and CXCR4 activates downstream signaling pathways such as G protein-mediated pathways (PI3K, ERK1/2, MAPK, and NF-κB), triggers intracellular Ca2+ release, increases neuronal excitability, and promotes pain generation.39,40 Additionally, this signaling axis regulates Nav1.8 channels in DRG neurons and is associated with the pathogenesis of mechanical allodynia and small fiber neuropathy observed in painful diabetic neuropathy mouse models.41

CCL3, also known as macrophage inflammatory protein-1α (MIP-1α), has been found to participate in the development of neuropathic pain through its predominant receptors CCR1 and CCR5.42 CCL3 is present in neurons, and studies have discovered that primary cultured microglia produce CCL3 upon ATP stimulation. The activated CCL3 can recruit macrophages/microglia and exacerbate inflammatory neuropathic pain.43–45 CXCL13, also called B lymphocyte chemoattractant (BLC), was originally found to be produced by stromal cells within B-cell follicles. CXCR5 is the sole receptor for CXCL13, also known as cluster of differentiation 185 (CD185) or Burkitt lymphoma receptor 1 (BLR1).46 Both CXCL13 and CXCR5 are expressed in the sensory nervous system, including peripheral sensory ganglia, spinal dorsal horn neurons, and astrocytes. They may contribute to neuropathic pain through neuron-astrocyte interactions. Moreover, CXCR5 can promote the activation of downstream signaling pathways such as NF-κB signaling, excessive activation of spinal cord glial cells, activation of c-Fos protein, and upregulation of pro-inflammatory cytokine IL-6, thereby causing mechanical allodynia.47 Upregulated expression of CXCL13/CXCR5 on DRG neurons can also enhance Nav1.8 channel expression, further contributing to inflammatory pain.48

Additionally, the use of chemokine receptor antagonists was shown to alleviate neuropathic pain, indicating the significance of chemokines in pain initiation. Following peripheral nerve injury (PNI), neuroinflammation occurs in the spinal cord, characterized by the activation of astrocytes and the upregulation of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2 (CCL2), and chemokine (C-X-C motif) ligand 1 (CXCL1). Inhibition of these factors in a rat model of pain demonstrated an improvement in symptoms associated with neuropathic pain.49

Based on the above, it can be concluded that various cell factors may be involved in the mechanisms of neuropathic pain, exerting different effects. These factors not only directly stimulate central or peripheral sensitization but also influence other cells or pathways, leading to the secretion of additional nociceptive factors and exacerbating pain.

Effect of Microglia on the Sensitization of Pain Sense
In 2003, Jin et al50 and Tsuda51 conducted experiments that revealed the significant role of spinal microglia in neuropathic pain. The development of microglia is controlled by the colony stimulating factor 1 receptor (CSF1R)52 and its corresponding ligand
interleukin-34 (IL-34).\textsuperscript{53} Transforming growth factor-β1 (TGF-β1) is also a crucial factor at the molecular level in promoting the differentiation and acquisition of mature properties in microglia.\textsuperscript{54} However, during the occurrence of pain, TGF-β plays a role in inhibiting the activity of spinal cord glial cells and can reduce the expression of CCL-2, thereby increasing the integrity of the blood-spinal-cord barrier (BSCB) and reducing further infiltration of immune cells into the spinal dorsal horn. It can also suppress inflammation through various pathways such as TGF-β/Smad, NF-κB/ERK1/2,\textsuperscript{55,56} thereby alleviating neuropathic pain. The inhibitory effects of TGF-β on neuropathic pain can also occur through gene transcription and neuroregulatory pathways in the dorsal root ganglion. TGF-β can rapidly activate TGF-β receptors on neurons, leading to the normalization of heightened excitability in the dorsal root ganglion and synaptic plasticity in the spinal cord induced by nerve injury.\textsuperscript{57}

Microglial activation can be triggered through toll-like receptor-4 (TLR4) or triggering receptor expressed on myeloid cells 2 (TREM2) expressed on trigger receptors, or via Caspase-mediated immune responses, which initiate pro-inflammatory signaling pathways such as the NF-κB and MAPK pathways. Activation of NF-κB pathway can induce the release of pro-inflammatory cytokines, primarily IL-1β and TNF-α, as well as chemokines like MCP1 and CXCL1. On the other hand, activation of the MAPK family including ERK1/2, p38, and JUN-amino-terminal kinase (JNK) pathway can upregulate the expression of pro-inflammatory genes regulated by AP-1 transcription factor, including COX2 and NOS2, further exacerbating inflammatory responses.\textsuperscript{58} Furthermore, interferon regulatory factor 8 (IRF8) is upregulated in microglia after peripheral nerve injury and regulates cellular genes and responses. This includes purinergic P2 receptors (P2X4R and P2Y12R), TLR2, CX3CR1, diffusion factor IL-1β, histone S, and brain-derived neurotrophic factor (BDNF), all of which collectively mediate the inflammatory response.\textsuperscript{59}

The red nucleus (RN) can bidirectionally regulate the development and maintenance of mononeuropathic pain by secreting both pro- and anti-inflammatory cytokines.\textsuperscript{60} Li et al\textsuperscript{61} observed a mononeuropathic pain model in rats with sciatic nerve injury (SNI) and discovered an increased expression of IL-33 and its receptor ST2 in RN neurons, oligodendrocytes, and microglia. This indicates that the activation of microglia induced by pain not only stimulates inflammatory responses around the affected tissues but also affects microglia activation in various regions such as the thalamus, amygdala, ventral tegmental area, anterior cingulate cortex, hippocampus, and periaqueductal gray matter.\textsuperscript{62–65}

It can be understood that microglia play a crucial role in the development, maintenance, and alleviation of neuropathic pain. Following nerve injury, microglia not only act as immune cells to repair the damaged area but can also initiate inflammatory cascades, leading to an increase in the recruitment of inflammatory cytokines and cells within the damaged region. Moreover, microglia can interact with various cell types, ultimately contributing to the onset of pain (Figure 2).

**Figure 2** The cytokines in neuropathic pain.
Effect of Ion Channels on Nociceptive Sensitization

The ion channels associated with chronic pain consist of Nav1.7, a voltage-gated sodium channel, and Kv1.1 and Kv1.2, voltage-gated potassium channels. By controlling the levels of proteins associated with calcium ($\text{Ca}^{2+}$), sodium ($\text{Na}^+$), potassium ($\text{K}^+$), and chloride ($\text{Cl}^-$), it is possible to alleviate symptoms of neuropathic pain.

Potassium Ion Channels

Kv plays a crucial role in regulating the excitability of neurons by controlling the resting membrane potential and repolarization. In rats, the downregulation of Kv1.2 expression in the dorsal root ganglion (DRG) and the dorsal horn of the spinal cord occurred as a result of chronic constrictive injury (CCI). This downregulation led to significant mechanical sensitization and hyperalgesia. Alongside the decrease in Kv1.2 expression, there was an increase in miR-137 expression. However, inhibiting miR-137 reversed these effects by increasing Kv1.2 expression in CCI rats. This restoration of abnormal Kv currents and excitability in dorsal root ganglia (DRG) neurons alleviated mechanical heterotopic pain and hyperalgesia. Kv1.2 is highly expressed in large and medium-sized DRG neurons, and its reduced expression can increase the excitability of DRG neurons, leading to mechanical, thermal, and cold hypersensitivity. The decrease in Kv1.2 expression can depolarize the resting membrane potential and lower the current threshold for generating action potentials in injured DRG neurons. It may also increase the release of primary afferent neurotransmitters regulated by mu opioid receptors (MOR), thus promoting the occurrence and maintenance of neuropathic pain hypersensitivity induced by peripheral nerve damage.

K2p1.1 is abundantly present in DRG neurons and facilitates the outward flow of potassium ions across the cell membrane. Decreased expression of K2p1.1 leads to membrane depolarization and increased neuronal excitability, rendering them sensitive to mechanical and thermal stimuli. In a study by Jia et al, it was found that systemic administration of paclitaxel resulted in a time-dependent reduction in K2p1.1 mRNA and protein expression in DRG neurons, leading to mechanical and thermal hypersensitivity in rats. Additionally, overexpression of ten-eleven translocation methylcytosine dioxygenase 1 (TET1) in DRG improved the expression of K+ channel 1.1 (K(2p)1.1) and alleviated mechanical heterotopic pain as well as heat and cold pain on the affected side in rats. These findings collectively highlight the significant impact of K+ channel regulation on pain relief.

Sodium Ion Channels

The sodium leak channel (NALCN) is a channel that allows the leakage of sodium ions and controls the excitability and rhythmicity of neurons. In a study by Zhang et al, it was discovered that NALCN is present in the DRG and dorsal spinal cord. When chronic compressive injury (CCI) occurred, NALCN currents and neuronal excitability increased. However, when NALCN was suppressed using NALCN-siRNA or NALCN-shRNA, pain-related symptoms in rats were relieved or eliminated. This suggests that NALCN is involved in neuronal sensitization caused by CCI.

Voltage-gated sodium channels (VGSCs) are crucial for perceiving pain. Nociceptors, which are sensory neurons in the peripheral nervous system, predominantly express different types of Nav channels, including Nav1.1, Nav1.3, Nav1.6, Nav1.7, Nav1.8, and Nav1.9. Studies in humans and mice have shown that Nav1.7 is vital for transmitting pain signals. Nav1.7 in humans is involved in generating and transmitting neuropathic and nociceptive pain signals. It enhances the effectiveness and selectivity of Nav isoforms, which is important for acute and chronic inflammatory pain models and neuropathic pain. Nav1.7 is widely expressed in all sensory neuron subtypes except proprioceptors, as demonstrated by a study.

Pulsed radiofrequency treatment has been effective for neuropathic pain, and research by Hidaka et al on the treatment of resiniferatoxin (RTX)-induced mechanical heterotopic pain suggests that pain relief may be linked to voltage-gated Na$^+$ channels. In a rat model of RTX-induced mechanical heterotopic pain in the DRG, the Nav1.7 channel was upregulated following increased phosphorylation of kinases regulated by extracellular signaling. Early combination therapy of tramadol could inhibit the upregulation of Nav1.7 in the DRG and alleviate pain symptoms. Nav1.7, a subtype of voltage-gated sodium channels, plays a crucial role in transmitting pain signals. Li et al discovered that a specific small-molecule inhibitor of CRMP2 SUMOylation, compound 194, selectively reduced Nav1.7 currents in DRG neurons across species and partially reversed mechanical heterotopic pain caused by nerve injury and chemotherapy.
**Calcium Channels**

Ziconotide is the initial medication that specifically blocks N-type voltage-sensitive calcium channels. By blocking these channels in the spinal cord, ziconotide prevents the release of pain-related neurotransmitters from the central terminals of primary afferent neurons, thus reducing pain. Painful diabetic neuropathy (PDN) is a condition characterized by neuropathic pain, where the nociceptors in the DRG become hyperexcitable, leading to excessive calcium levels, degeneration of axons, and loss of cortical innervation. George et al discovered that DRG neurons in PDN mice induced by a high-fat diet expressed a significant amount of a protein involved in mitochondrial fission. Examples of proteins involved in mitochondrial dynamics include dynamin-related protein 1 (Drp1), Mitochondrial Fission 1 protein (Fis1), mitochondrial fission factor (Mff), optic atrophy 1 (Opa1), among others. Fis1 and Mff serve as receptors recruiting Drp1 to mitochondria. Mff, a GTP hydrolysis enzyme, catalyzes mitochondrial fission in cells by forming a complex with GTPase Drp1 to promote the process. The normal activity of various pumps and transporters on the membrane of peripheral sensory neurons, as well as long-range transport along the nerve sheath, requires substantial ATP supply. Dysregulation of Drp1, Fis1, Dnm2, and Dnm3 contributes to increased reactive oxygen species (ROS) levels within cells. Furthermore, mitochondrial dysfunction leads to enhanced ROS production, loss of mitochondrial membrane potential, uncoupling of the electron transport chain, and decreased ATP concentration. These factors result in insufficient energy supply and dysfunction of peripheral sensory neurons, ultimately contributing to the occurrence of pain.

Furthermore, nociceptive receptors exhibited increased calcium signals in these mice. This particular type of neuropathic pain seems to be associated with axonal degeneration. When there is hyperexcitability of nociceptive receptors and an elevated calcium concentration within the affected cells, excess calcium ions are transported into the mitochondria via the mitochondrial calcium uniporter. This results in increased calcium-dependent mitochondrial fission, ultimately leading to axonal degeneration and neuropathic pain in PDN. Pulsed radiofrequency treatment with high voltage and prolonged duration has proven effective for neuropathic pain. However, the Cav2.2 channel can increase neuronal excitability and neurotransmission, contributing to neuropathic pain. By inhibiting the Cav2.2 channel, the hyperalgesic behaviors caused by NP can be reversed. Neuromedin B (Nmb) is involved in the regulation of nociception in sensory neurons. Zhang et al found that NmbR, by enhancing Cav3.2 channel currents, increases neuronal excitability in small trigeminal ganglion cells, leading to pain sensitization in a mouse model of inflammatory pain. In another study by Qi et al, it was shown that miR-32-5p targeted and inhibited Cav3.2 T-type calcium channels. In a rat model of trigeminal neuralgia, overexpression of miR-32-5p effectively suppressed Cav3.2 expression and relieved mechanical heterotopic pain.

**Chloride Channels**

Anoctamin-1 (ANO1), a calcium-activated chloride channel, has the potential to be a target for pain relief. ANO1 is activated by harmful stimuli transmitted from sensory neurons in the peripheral nervous system, leading to nerve depolarization. Decreasing the activity of ANO1 alleviates hyperpathia and heterotopic pain resulting from inflammation and nerve damage. Reduced glycnergic inhibition could be a spinal mechanism underlying the manifestation of pathological pain symptoms. An increase in sensitivity to mechanical, thermal, and cold stimuli can result from the disruption of glycine receptors, a type of ion channel that permits the passage of chloride ions. Particularly, the glycine receptor α1 subunit in the adult spinal cord is essential for the production of inhibitory neurotransmitters. In a study conducted by Yao et al, changes in the glycine receptor α1 subunit were observed in mice experiencing inflammation induced by formalin, and administration of glycine receptor agonists alleviated the aforementioned pain symptoms. These findings suggest that altered expression of glycine receptors or chloride channels may impact pain mechanisms. Liao et al demonstrated that using low-intensity focused ultrasound (LIFU) has the ability to hinder calcium/calmodulin-dependent protein kinase type IV (CaMKIV) and activate the potassium chloride co-transporter 2 (KCC2) pathway in neurons located in the spinal dorsal horn. This activation leads to alleviation of neuropathic pain behavior in rats with peripheral nerve injury (PNI). From this, it can be concluded that regulating levels of calcium (Ca$^{2+}$), potassium (K$^+$), chloride (Cl$^-$), and expression of their associated proteins may provide relief from neuropathic pain.

Lorenzo et al discovered that a ligand called L838,417, which targets the benzodiazepine site, plays a significant role in analgesia. However, when administered at high doses, L838,417 failed to induce analgesia due to impaired
chloride ion efflux. Conversely, increasing the activity of KCC2 not only enhanced the analgesic effects of L838,417 but also restored its potential to alleviate pain at high doses. This suggests that maintaining chloride ion homeostasis is crucial for analgesia in cases of pathological pain.

Additionally, other proteins related to ion channels, such as P2X7R protein or the transient receptor potential M8 (TRPM8) ion channel, can also influence pain modulation to some extent.

Unlike cell factors, ion channels primarily function by altering the resting membrane potential on the cellular membrane or by facilitating the release of pain-inducing neurotransmitters. Such pathological mechanisms provide avenues for exploring new drugs and therapeutic approaches to address pain.

**Effect of Synaptic Proteins on the Sensitization of Pain Sense**

Chronic pain is characterized by changes in the dorsal horn of the spinal cord known as synaptic plasticity. This refers to the ability of synapses in this region to undergo long-term potentiation (LTP) and long-term depression (LTD), which are influenced by activity and contribute to central sensitization in chronic pain. The stimulation of the primary afferent tract through burst stimulation (TBS) typically leads to LTP, while tetanic stimulation often results in LTD. The occurrence of synaptic LTP in spinal projection neurons is associated with the development of chronic pain. When primary afferent nerves discharge, closely linked to layer I projection neurons, they can induce synaptic LTP. This, in turn, increases injurious currents in the dorsal horn of the spinal cord, causing intense nociceptive sensations.

Li et al.\(^92\) discovered that the activation of mGluR5 and intracellular Ca\(^{2+}\) together led to the activation of spinal D1/D5Rs, which facilitated the transition from Hebbian LTP to non-Hebbian LTP. This activation also altered the discharge frequencies of presynaptic and postsynaptic neurons. Primary afferent stimulation alone was sufficient to induce LTP even without action potential discharge in projection neurons. As a result, the sensory synapses on the output neurons that send pain information to the brain were significantly strengthened.

Liu et al.\(^93\) found that a reduction in glutamatergic synaptic connection strength in the ventral periaqueductal gray (vPAG) region was associated with increased abdominal sensitivity caused by dibutylin dichloride (DBTC). This decrease was a result of both pre- and post-synaptic mechanisms. However, they also discovered that activation of AMPA receptors in vPAG could alleviate DBTC-induced abdominal sensitivity. These findings emphasize the significance of synapses in pain mechanisms and the potential of modulating central mechanisms to influence peripheral pain.

Dong et al.\(^94\) further demonstrated the importance of NMDARs in pain modulation. They observed a significant upregulation of the α2δ-1 protein encoded by Cacna2d1 in DRG neurons and the spinal dorsal horn after sensory nerve injury. This upregulation enhanced the activity of pre- and post-synaptic NMDARs in spinal dorsal horn neurons, leading to sensitization of pain perception. Xie et al.\(^95\) conducted a study showing that pre-synaptic NMDARs (PreNMDARs) located at the terminals of spinal pain receptors played a crucial role in activity-dependent pain sensitization. In normal organisms, PreNMDARs inhibit presynaptic transmission, but in injured organisms, they induce presynaptic potentiation.

**Interaction of Various Mechanisms**

The activation of microglia and their involvement in the development and progression of neuropathic pain can be facilitated by P2X7R. In a study conducted by Wu et al.\(^96\) an agonist of P2X7R called 2′(3′)-o-(4-benzoyl)benzoyl ATP (BzATP) was utilized along with electroacupuncture stimulation as a treatment for a rat model of spinal nerve ligation (SNL). The findings demonstrated that electroacupuncture treatment led to a decrease in dendritic spine density, inhibited synaptic remodeling, and reduced the inflammatory response. These effects were consistent with the decrease in P2X7R expression and the improvement of neurobehavioral performance. Conversely, BzATP enhanced abnormal remodeling and inflammation of dendritic spines and synapses. Hence, it was concluded that electroacupuncture may alleviate neuropathic pain by reducing abnormal remodeling of dendritic spines and synapses, as well as improving inflammation through the inhibition of P2X7R expression. Spinal cord injuries result in permanent loss of motor and sensory functions due to complex mechanisms involving the external microenvironment and internal neuro-biochemistry, which limit neuronal plasticity and axonal regeneration. In a study by Li et al.\(^97\) it was discovered that the CXCL12 peptide promoted elongation of axons, branch formation, dendrite formation, and synapse formation, leading to alleviation of symptoms associated with spinal cord injuries and enhancement of neurological function.
recovery. This suggests that chemokines not only influence the inflammatory response but also directly impact synapses, consequently affecting neuropathic pain. Microglia activation encompasses processes such as proliferation, migration, cytokine release, and production of reactive oxygen species which rely on changes in ion homeostasis involving calcium (Ca\(^{2+}\)), sodium (Na\(^{+}\)), potassium (K\(^{+}\)), chloride (Cl\(^{-}\)), and hydrogen (H\(^{+}\)). These changes are facilitated by ion channels and transporters within microglia. High voltage-activated calcium channels that are crucial for synaptic transmission in sensory neurons can be targeted for analgesic purposes. In mice with nerve damage, there is a significant increase in synchronized firing of neurons in the dorsal root ganglion, leading to persistent mechanical, heat, and cold sensitization.

The study conducted by Sun et al.\(^9\) involved the application of a powerful genetically encoded blocker called CAV-AβLator to inhibit the increase of Ca\(^{2+}\) signaling in DRG neurons following SNI and HVACC currents. This intervention led to the alleviation of SNI-induced mechanical heterotopic pain and sensitization to hot and cold stimuli. In a separate study by Boinon et al.,\(^10\) it was discovered that collapsin response mediator protein 2 (CRMP2) serves as a dual regulator for both the n-type voltage-gated calcium (Cav2.2) channel and the Nav1.7 voltage-gated sodium channel. By selectively reducing the expression of CRMP2 in neurons, mechanical hyperalgesia in male and female mice caused by selective nerve injury was reversed. This pain mechanism appeared to be related to a decrease in the frequency and amplitude of spontaneous excitatory postsynaptic currents, suggesting that changes in neuronal ion levels might influence synaptic currents and contribute to CRMP2-mediated pain signal transduction.

**Complications**

Several studies have suggested that a significant percentage of patients (20–30%) with chronic pain experience negative emotions, such as anxiety, depression, aversion, and avoidance.\(^101–103\) These negative emotions have been found to potentially increase the perception of pain or reduce the ability to tolerate pain.\(^104\) The nucleus accumbens, specifically the medium spiny neurons (MSNs) within it, play a role in reward effects, regulation of motivation, and affective disorders. In a mouse pain model involving spinal nerve ligation (SNL), it was observed that the Ccl2-mediated CCL2/CCR2 signaling pathway in the nucleus accumbens was involved in integrating excitatory and inhibitory synaptic transmission in neuropathic pain. Furthermore, this pathway improved the state of long-term depression (LTD) induced by synapses in MSNs.\(^105\) Pain is often associated with poor sleep quality. An inverse relationship exists between the two: pain impairs sleep, which in turn lowers the body’s ability to tolerate pain.\(^106\) According to a study by Li et al.,\(^107\) increased inflammatory response is closely linked to chronic pain symptoms and sleep quality. By regulating the hypothalamus-pituitary-adrenal axis, this inflammatory response can be reduced, thereby alleviating pain and improving sleep quality. Cav3 channels, previously known as T-type low voltage-activated calcium channels, play a role in modulating neuronal excitability, sensory processing, sleep, and the release of hormones and neurotransmitters. Therefore, it can be inferred that regulating ion balance through Cav3 channels may improve sleep and pain symptoms.\(^108\) Blum et al.\(^109\) also demonstrated that modulation of Ca\(^{2+}\) channels contributes to sleep regulation. Sleep deprivation was found to affect the phosphorylation cycle of synaptic neurosomes, which influences synaptic transmission, cytoskeletal reorganization, and the balance between excitation and inhibition.\(^110\) Another study by Huang et al.\(^111\) highlighted the significance of synaptic plasticity in sleep regulation. Thus, it is clear that by modulating inflammatory mechanisms, maintaining ionic balance, and ensuring synaptic function, the complications associated with pain can be improved.

**Therapeutic Mechanisms of Analgesic Drugs (Table 1)**

Drug resistance or side effects often arise from prolonged use of NSAIDs and opioids, which are commonly prescribed in medical practice to manage pain. Morphine, a widely used painkiller, can develop tolerance with long-term use. With advancements in Traditional Chinese Medicine, certain extracts from Chinese patent medicine have emerged, demonstrating promising results in clinical pain relief. This diversifies the options for analgesic drugs and helps enhance the effectiveness of existing medications or alleviate their resistance to some extent. In a particular study, celastrol was found to reduce mechanical and heat-induced pain in rats with chronic constriction injury (CCI). The mechanism behind this effect was the inhibition of microglia and astrocyte activation in the rats’ spinal cord, subsequently reducing the expression of the toll-like receptor-4/nuclear factor kappa B (TLR4/NF-kB) signaling pathway and levels of pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), IL-1β, and IL-6 in the spinal cord.\(^112\) Corydalis yanhusuo has anti-inflammatory and analgesic properties due to its
Table 1 Pharmacological Profile of Analgesic Medications

<table>
<thead>
<tr>
<th>Drug Class or Name</th>
<th>Active Ingredient</th>
<th>Dosage</th>
<th>Mechanism of Action or Target</th>
<th>Side Effects</th>
<th>Approved by FDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine Sulfate (Opioids)</td>
<td>Morphine Sulfate</td>
<td>Initiate treatment with Morphine Sulfate Tablets in a dosing range of 15 mg to 30 mg every 4 hours for oral administration as needed for pain. Mild to moderate pain: 400 mg every 4 to 6 hours for oral administration as necessary for relief of pain.</td>
<td>Morphone is a full opioid agonist and is relatively selective for the MOR. Decrease prostaglandin synthesis by inhibiting cyclooxygenase (COX) activity.</td>
<td>Drowsiness, confusion, nausea, constipation, euphoria, slowed breathing and develop tolerance with long-term use. Increase the chance of a heart attack or stroke; can cause ulcers and bleeding in the stomach and intestines and et al</td>
<td>Yes*</td>
</tr>
<tr>
<td>Motrin (NSAIDs)</td>
<td>Ibuprofen</td>
<td></td>
<td></td>
<td></td>
<td>Yes**</td>
</tr>
<tr>
<td>Tripterygium wilfordii Hook F.</td>
<td>Celastrol</td>
<td>0.5, 1 and 2 mg/kg administered intraperitoneally once daily after the CCI operation from Day 3 to Day 14</td>
<td>Inhibiting the TLR4/NF-κB signaling pathway; TNF-α↓; IL-1β↓; IL-6↓</td>
<td>Rats with CCI-induced NP</td>
<td>Attenuate mechanical and thermal pain</td>
</tr>
<tr>
<td>Corydalis yanhusuo</td>
<td>Tetrahydropalmatine</td>
<td>40 mg/kg/d for 6 weeks</td>
<td>Suppress the p38 MAPK signaling pathway; NO↓; TNF-α↓; IL-1β↓; IL-6↓; IL-10↑</td>
<td>Diabetic neuropathic pain rat model</td>
<td>Improve Mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL)</td>
</tr>
<tr>
<td>NeuroHeal</td>
<td>Acamprosate and ribavirin</td>
<td>0.05×, 0.2×, 1×, 1.7× and 3× dose for 21d</td>
<td>Modulate the P2X4-BDNF-KCC2 axis; enhances motor axon regeneration; sirtuin-1↑; anti-microgliosis</td>
<td>Peripheral nerve injury rat model</td>
<td>Reduces Hyperalgesia and Mechanical Allodynia</td>
</tr>
</tbody>
</table>

active ingredient Tetrahydropalmatine (THP). Cheng et al. treated rats with DNP using an extract of THP and observed that it promoted a shift from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype in lipopolysaccharide-induced BV2 microglia. This extract also inhibited the activation of the p38 MAPK signaling pathway, reduced expression levels of inflammatory factors such as NO, IL-1β, IL-6, and TNF-α, increased expression level of anti-inflammatory factor IL-10, and alleviated inflammatory response around the lesions, ultimately improving pain symptoms in the rats. Furthermore, novel medications have been developed to target pain mechanisms. One example is NeuroHeal, a recently developed drug that combines acamprosate and ribavirin. NeuroHeal promotes the regeneration of motor and sensory axons following peripheral nerve injury (PNI), alleviates the distressing sensation of pain caused by diseases, and modulates the P2X4-BDNF-KCC2 axis, a crucial factor in neuropathic pain. Ultimately, NeuroHeal proves effective in alleviating neuropathic pain resulting from PNI. In summary, recent focus in the field of analgesic drugs has been on exploring Chinese herb extracts and developing new medications that target pain. Additionally, ongoing research aims to improve the utilization of existing drugs, enhance their effectiveness in combination, and mitigate potential toxic side effects they may cause.

Conclusions
Altering the inflammatory state of the body remains a meaningful approach to pain relief, and various mechanisms of pain can establish a connection between the peripheral and central nervous systems. The abnormal activation of pro-inflammatory substances contributes to the formation, progression, maintenance, and intensification of neuropathic pain. Disturbances in ions and changes in synaptic function are also implicated in pain and its complications (Figure 3). While new drugs with primarily anti-inflammatory mechanisms are emerging in clinical practice, recent findings suggest that altered synaptic function and ionic balance are also associated with pain. Therefore, considering other mechanisms in the development of new drugs could be a promising direction for future drug research and development. However, studies have suggested that nonsteroidal anti-inflammatory drugs may not provide significant relief for neuropathic pain. Nevertheless, extensive research on the role of inflammatory mechanisms in pain cannot be ignored, emphasizing the need to examine the effectiveness of multiple inflammatory pathways in neuropathic pain. Identifying specific factors and elucidating the precise mechanisms underlying disease development are crucial for targeted therapies and diagnosing underlying mechanisms. Ion channels have shown potential in improving pain symptoms, and it is also vital to consider the normal activity of cardiac cells and higher central nervous system neurons in the cerebral cortex, as they are sensitive to changes in membrane ion dynamics. These aspects should not be overlooked in future research endeavors.

Figure 3 The mechanisms for pain.
Abbreviations

IASP, The International Association for the Study of Pain; NP, neuropathic pain; CX3CL1, chemokine C-X3-C motif ligand 1; CSF1R, colony stimulating factor 1 receptor; IL-34, interleukin-34; TGF-β1, transforming growth factor β1; TLR4, Toll-like receptor 4; TREM2, triggering receptor expressed on myeloid cells 2; PNI, peripheral nerves injuries; LIFU, Low-intensity focused ultrasound; CaMKIV, calmodulin-dependent protein kinase 2; LTP, long-term potentiation; LTD, long-term depression; RTX, resiniferatoxin; NALCN, sodium leak voltage gated sodium channels; NAc, nucleus accumbens; Nmb, neuromedin B; TET1, ten-eleven translocation methylcytosine dioxygenase 1; Kv, voltage-gated potassium channel; MSNs, medium spiny neurons; CRMP2, collapsin response mediator protein 2; LTP, long-term potentiation; LTD, long-term depression; RTX, resiniferatoxin; NALCN, sodium leak channel; PNI, peripheral nerves injuries; LIFU, Low-intensity focused ultrasound; CaMKIV, calmodulin-dependent protein kinase IV.

Disclosure

The authors report no conflicts of interest in this work.

References


